BLCO · Bausch & Lomb Corp
$16.28
+0.09 (+0.56%)
At close · Jul 27
Market Cap
$5.80B
Shares
356.54M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$5.1B
+6.5%
FY2025
Net Income
-$360M
-13.6%
FY2025
Operating Margin
2.22%
-1.2pp
FY2025
Diluted EPS
-$1.02
-13.3%
FY2025
Operating Cash Flow
$283M
+22%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|---|
| $5.42B – $5.52B | $5.21B | $5.1BG | $4.79B | $4.15B | $3.77B | $3.77B | $3.41B | |
| — | $386M | $371M | $343M | $324M | $307M | $271M | $253M | |
| — | $2.22B | $2.23B | $2.08B | $1.74B | $1.48B | $1.39B | $1.25B | |
| — | — | $421M | $436M | $382M | $379M | $415M | $442M | |
| — | $65M | $58M | $26M | $44M | $14M | $2M | $2M | |
| — | $4.98B | $4.99B | $4.63B | $4.02B | $3.56B | $3.44B | $3.15B | |
| — | $229M | $113M | $162M | $130M | $207M | $329M | $260M | |
| — | — | 2.22% | 3.38% | 3.14% | 5.49% | 8.74% | 7.62% | |
| — | — | $534M | $598M | $512M | $586M | $744M | $702M | |
| — | $13M | $12M | $15M | $15M | $6M | $0 | $3M | |
| — | -$74M | — | — | -$74M | -$13M | -$17M | -$38M | |
| — | -$201M | -$317M | -$234M | -$166M | $73M | $318M | $290M | |
| — | $10M | $35M | $71M | $82M | $58M | $125M | $307M | |
| — | -$219M | -$360M | -$317M | -$260M | $6M | $182M | -$18M | |
| — | — | -7.06% | -6.62% | -6.27% | 0.16% | 4.83% | -0.53% | |
| — | $8M | $8M | $12M | $12M | $9M | $11M | $1M | |
| — | -$114M | -$159M | -$457M | -$247M | -$217M | $36M | $139M | |
| USD/shares | — | — | -$1.02 | -$0.90 | -$0.74 | $0.02 | $0.52 | -$0.05 |
| USD/shares | — | — | -$1.02 | -$0.90 | -$0.74 | $0.02 | $0.52 | -$0.05 |
| shares | — | — | 353.8M | 351.8M | 350.5M | 350M | 350M | 350M |
| shares | — | — | 353.8M | 351.8M | 350.5M | 350.2M | 350M | 350M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
2.03×
Peer median 2.72×
EV/EBIT
46.18×
Peer median 32.19×
P/E (TTM)
—
Peer median 39.39×
Peer medians compare against the 27 similar-size Medical Instruments & Supplies companies (of 50 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Vision Care | $2,923,000,000 | $2,739,000,000 | $2,543,000,000 | $2,369,000,000 | $2,327,000,000 | $2,109,000,000 |
| Pharmaceuticals | $1,284,000,000 | $1,209,000,000 | $836,000,000 | $681,000,000 | $720,000,000 | — |
| Surgical | $894,000,000 | $843,000,000 | $767,000,000 | $718,000,000 | $718,000,000 | $577,000,000 |
| Ophthalmic Pharmaceuticals | — | — | — | $677,000,000 | $704,000,000 | $726,000,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| United States and Puerto Rico | $2,546,000,000 | $2,413,000,000 | $1,934,000,000 | $1,695,000,000 | $1,618,000,000 | $1,558,000,000 |
| Other Countries | $777,000,000 | $712,000,000 | $655,000,000 | $616,000,000 | $572,000,000 | $516,000,000 |
| China | $358,000,000 | $358,000,000 | $344,000,000 | $343,000,000 | $390,000,000 | $280,000,000 |
| France | $246,000,000 | $227,000,000 | $210,000,000 | $195,000,000 | $201,000,000 | $174,000,000 |
| Japan | $186,000,000 | $180,000,000 | $187,000,000 | $192,000,000 | $224,000,000 | $220,000,000 |
| Germany | $164,000,000 | $152,000,000 | $147,000,000 | $138,000,000 | $149,000,000 | $137,000,000 |
| Russia | $148,000,000 | $120,000,000 | $106,000,000 | $132,000,000 | $116,000,000 | $102,000,000 |
| United Kingdom | $137,000,000 | $132,000,000 | $121,000,000 | $108,000,000 | $111,000,000 | $84,000,000 |
| Canada | $135,000,000 | $127,000,000 | $110,000,000 | $101,000,000 | $101,000,000 | $92,000,000 |
| Italy | $102,000,000 | $91,000,000 | $82,000,000 | $72,000,000 | $75,000,000 | $67,000,000 |
| Spain | $101,000,000 | $92,000,000 | $85,000,000 | $77,000,000 | $80,000,000 | $66,000,000 |
| Mexico | $75,000,000 | $75,000,000 | $68,000,000 | $55,000,000 | $40,000,000 | $32,000,000 |
| Poland | $75,000,000 | $65,000,000 | $51,000,000 | $44,000,000 | $42,000,000 | $36,000,000 |
| South Korea | $51,000,000 | $47,000,000 | $46,000,000 | — | $46,000,000 | $48,000,000 |
| Belarus | — | — | — | — | — | $8,000,000 |
| Ukraine | — | — | — | — | — | $14,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Device Products | $1,922,000,000 | $1,800,000,000 | $1,650,000,000 | $1,572,000,000 | $1,596,000,000 | $1,314,000,000 |
| Over the Counter Products | $1,834,000,000 | $1,724,000,000 | $1,611,000,000 | $1,461,000,000 | $1,394,000,000 | $1,310,000,000 |
| Pharmaceutical Products | $1,081,000,000 | $969,000,000 | $618,000,000 | $468,000,000 | $493,000,000 | $508,000,000 |
| Branded and Other Generic Products | $243,000,000 | $281,000,000 | $252,000,000 | $245,000,000 | $254,000,000 | $249,000,000 |
| Other Revenues | $21,000,000 | $17,000,000 | $15,000,000 | — | — | — |
| Product And Service Other | $21,000,000 | $17,000,000 | $15,000,000 | $22,000,000 | $28,000,000 | $31,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Vision Care | $849,000,000 | $808,000,000 | $689,000,000 | $636,000,000 | $576,000,000 | $579,000,000 |
| Pharmaceuticals | $258,000,000 | $256,000,000 | $241,000,000 | $203,000,000 | $301,000,000 | — |
| Surgical | $18,000,000 | $44,000,000 | $50,000,000 | $42,000,000 | $75,000,000 | $18,000,000 |
| Ophthalmic Pharmaceuticals | — | — | — | $202,000,000 | $290,000,000 | $302,000,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Vision Care | 29% | 29.5% | 27.1% | 26.8% | 24.8% | 27.5% |
| Pharmaceuticals | 20.1% | 21.2% | 28.8% | 29.8% | 41.8% | — |
| Surgical | 2% | 5.2% | 6.5% | 5.8% | 10.4% | 3.1% |
| Ophthalmic Pharmaceuticals | — | — | — | 29.8% | 41.2% | 41.6% |
Key facts
CIK
1860742
CUSIP
071705107
13F (30d)
10 filings
10 filers
Visit website
Investor relations